News Conference News ESC 2025 WHF Stresses the Importance of Polypills in Global Fight Against CVD Yael L. Maxwell September 09, 2025
News Daily News High-Sensitivity Troponin Tests Might Aid in Primary Prevention Yael L. Maxwell April 16, 2025
News Daily News FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy L.A. McKeown November 25, 2024
News Daily News Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA Caitlin E. Cox June 25, 2024
News Daily News Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial Michael O'Riordan December 27, 2023
News Conference News ACC 2023 CRP More Predictive of Future Events Than LDL in Statin-Treated Patients Caitlin E. Cox March 14, 2023
News Daily News CT Angiography Is Increasing in England, but Downstream Tests Are Not Michael O'Riordan January 12, 2023
News Daily News P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis Todd Neale November 21, 2022
News Conference News ESC 2022 P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER Todd Neale August 29, 2022
News Daily News New Chest Pain Guidelines Out at Last: Most Tests Have a Role Michael O'Riordan October 28, 2021
News Daily News Rivaroxaban-Aspirin Combo Works in ASCVD Across BMI Groups Todd Neale February 01, 2021
News Daily News Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans Michael O'Riordan May 15, 2020
News Daily News Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES Michael O'Riordan May 04, 2020
News Conference News ACC 2020 Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events Michael O'Riordan April 02, 2020
News Conference News ACC 2020 Colchicine Cost-effective in Canada, and Even in the US: COLCOT Caitlin E. Cox March 28, 2020
News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Conference News ESC 2019 Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics Yael L. Maxwell September 03, 2019
News Daily News Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES Michael O'Riordan August 26, 2019